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ratio (ICUR) ranged from 11,921 to 17,215 CNY (1889 to 2728 US dollars, 2012) per 
QALY saved. All of the ICURs were much less than China’s GDP per capita (6247 US 
dollars, 2012). ConClusions: VIA screening at different intervals were all very cost-
effective options for 35-59 years old women in rural China. It is also noted that the 
cost-effective manner of aselected strategy largely depends on the local economic 
status and the performance of such organized program.
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ECoNomiC EvaluatioN of HomE ParENtEral NutritoN iN CaNCEr 
PatiENts; tHE frENCH CoNtExt
Hashim M.S., Povero M., Aliano A., Pradelli L.
AdRes HE&OR, Turin, Italy
objeCtives: This study aims to estimate incremental cost and utility of Home 
Parenteral Nutrition (HPN) in a heterogeneous group of cancer patients from the 
French public purchaser perspective, as compared with the same patients receiving 
no HPN. Methods: Two economic models, from public French perspective, were 
defined: a 28 day cost-utility model and a lifetime state transition model; both 
models were based on ecological data from an extensive literature search. Four 
health states were used in the second model: Home, two hospitalization states 
and death. Transition to death state was based on survival analysis obtained from 
published summary statistics from two different studies. Functional Assessment 
Cancer Therapy-general (FACT-g) scores, reported in a recently published French 
observational study, were used to compute utility weights in the intervention group 
by applying relevant published algorithms. In the control groups, they were com-
puted by decrementing the baseline utility weight of the intervention group. All 
costs: nutrition costs, resources consumption costs, complication costs and hospi-
talization costs were adapted from published French studies. Both Deterministic 
and Probabilistic Sensitivity Analyses were performed to test uncertainty. Results: 
The cost-utility ratio of HPN is estimated in 508,059 and 182,584 Euro per QALY gain, 
in the 28 day cost-utility model and the lifetime state transition model, respectively. 
DSA showed that survival in the control group and cost of the nutrition were the 
most influential parameters on the cost-utility ratio in both models. The probability 
for cost-effectiveness, considering a willingness to pay (WTP) 87,000 Euro (3XGDP 
per capita in France) for a QALY, was below 1% in both models. ConClusions: 
Final judgment on HPN cost-effectiveness is difficult, even if it seems to be not cost-
effective according to standard WTP. The high cost-utility ratio, which declines with 
increasing survival benefits, should urge clinicians and policy makers to control the 
sources of ineffectiveness.
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Cost-EffECtivENEss aNalysis of ugt1a1 gENotyPiNg BEforE 
ColorECtal CaNCEr trEatmENt witH iriNotECaN
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objeCtives: Irinotecan is an anti-cancer agent that is used for the treatment of 
metastatic colorectal cancer. Although it prolongs survival, it can cause severe toxic-
ity (e.g. diarrhea and neutropenia) in patients who carry the UGT1A1*28 allele. This 
study evaluates the cost-effectiveness of UGT1A1 genotyping prior to irinotecan-
based chemotherapy from the perspective of the German statutory health insur-
ance. Methods: We develop a decision-analytic Markov model to analyze costs 
and QALYs during a time horizon of six months (two-week cycles). No testing was 
compared to (1) change of chemotherapy to an irinotecan-free regimen, (2) dose 
reduction of irinotecan-based chemotherapy and (3) administration of a prophy-
lactic G-CSF growth factor for patients with a UGT1A1*28 variant. Probability, utility 
and cost parameters used in this study were extracted from published literature. 
Uncertainty was assessed by deterministic and probabilistic sensitivity analy-
ses. Results: Strategy (2) was the cheapest strategy associated with costs of about 
€ 12,600 and effects of approx. 0.32 QALYs. All other three strategies were absolutely 
dominated. Compared to no testing, strategy (2) resulted in only marginal increases 
of QALYs (0.0003) but reduced costs by about € 1,500 per patient. Strategy (1) resulted 
in smaller health gains (0.0002 QALYs) and smaller cost savings (about € 60). Strategy 
(3) yielded approximately the same QALY gains as strategy (2) but at higher costs. In 
the probabilistic analysis, strategy (2) was the optimal strategy in 52% of simulations 
at a threshold of € 50,000 per QALY. Uncertainty for this strategy originated primarily 
from the utility weights and the costs of chemotherapy. ConClusions: Our analy-
sis suggests that UGT1A1 genotyping and subsequent reduction of irinotecan-based 
chemotherapy has a substantial cost-saving potential. Due to the promising results, 
further research, for example in the form of a managed entry agreement would be 
desirable to validate these findings.
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Cost-EffECtivENEss aNalysis of tEstiNg for BrCa mutatioNs iN 
womEN DiagNosED witH ovariaN CaNCEr aND tHEir fEmalE first-
DEgrEE rElativEs: a uk HEaltH sErviCE PErsPECtivE
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objeCtives: Mutations in BRCA1 and BRCA2 are associated with an increased risk 
of breast and ovarian cancer. If a mutation is detected in women with ovarian 
cancer their unaffected relatives can potentially undergo gene testing and cancer 
risk-reducing surgery. Current UK practice is for any such relative to have access 
to testing. Guidelines also recommend that gene testing should be offered to indi-
viduals with BRCA mutation carrier probability of ≥ 10%, although this is not rou-
tinely implemented. In particular, many eligible women with ovarian cancer are not 
offered BRCA testing. Our aim is to evaluate the long-term cost-effectiveness in the 
UK of providing BRCA testing to women with ovarian cancer and to the unaffected 
female first-degree relatives of those with BRCA mutations. Methods: A Markov 
model with a lifetime horizon was developed to reflect the clinical and economic 
1IMS Health, London, UK, 2Bristol-Myers Squibb, Rueil Malmasion, France, 3Bristol-Myers Squibb, 
Bromma, Sweden, 4Bristol-Myers Squibb Pharmaceuticals, Wallingford, CT, USA
objeCtives: Ipilimumab was the first compound to substantially prolong survival 
in advanced melanoma. Evaluate the cost-effectiveness of ipilimumab in untreated 
advanced melanoma compared to dacarbazine and vemurafenib from a Swedish 
national payer perspective (TLV/NLT). Methods: A three-state Markov model with 
stable disease, progression and death was developed, estimating costs and ben-
efits over a lifetime horizon. Given a lack of head-to-head data and a connected 
evidence network to allow for a robust NMA, the comparison used two sources of 
data unadjusted for study characteristics. Ipilimumab survival data were based 
on a pooled sample of treatment-naïve patients from clinical trials (n= 78) and 
real-world settings (n= 181), the clinical data package used for EMA submission. 
Parametric extrapolation methods were applied to dacarbazine data from CA184-
024. Mixture modelling was used to extrapolate vemurafenib data from BRIM-III. 
Resource use was taken from a survey of Swedish oncologists (n= 5). EORTC-8D 
utility data from an untreated population were used because they match the popula-
tion of interest. Costs were obtained from official Swedish price lists. Survival and 
utility assumptions were varied in scenario analyses. Results: Ipilimumab was 
associated with a 0.93 QALY gain and an ICER of SEK782,000 (€ 84,000) versus dacar-
bazine. Ipilimumab dominated vemurafenib with a 0.76 QALY gain and a SEK109,000 
(€ 15,000) cost-saving. The unadjusted comparison was the most conservative among 
alternative methods of clinical comparisons explored. The ICER versus dacarbazine 
was SEK521,000 (€ 56,000) using a published survival algorithm (7) and SEK532,000 
(€ 57,000) using a covariate-adjusted survival regression based on the 78-patient 
dataset. A real-world scenario using the patient shares of dacarbazine and vemu-
rafenib was also deemed cost-effective. ConClusions: As in the previously treated 
setting, ipilimumab produces large (> 0.5 year) survival and quality-adjusted sur-
vival gains relative to current treatments. TLV/ NLT considered ipilimumab a cost-
effective treatment for advanced melanoma based on these results.
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Cost-utility aNalysis of trastuzumaB iN trEatmENt of mEtastatiC 
HEr2-PositivE BrEast CaNCEr iN viEtNam
Nguyen T.T.C., Nguyen T.T.T.
University of Medicine and Pharmacy in HCMC, Ho Chi Minh City, Vietnam
objeCtives: Trastuzumab, a targeted therapy, has been widely used in treatment 
of HER2-positive breast cancer because of its proved effectiveness and safety by 
many studies but its economic impact with low-income countries like Viet Nam has 
not been assessed yet. The aim of this study is to evaluate the cost-effectiveness 
of trastuzumab in combination of standard therapy versus standard therapy in 
treatment of metastatic HER2-positive breast cancer. Methods: A Markov model 
was developed with 3 states (stable disease, progressive disease and death) to simu-
late a hypothetical cohort of 1,000 metastatic HER2-positive breast cancer women 
of an average age of 53 year old with the same entry criteria as in the M77001 
study group. Chemotherapy with ACD regimen (Doxorubicin, Cyclophosphamide, 
Docetaxel) was compared with ACD regimen plus trastuzumab. The cycle length of 
model was 1 month and time horizon was lifetime. Both cost and Quality-adjusted 
life-years (QALYs) were discounted annually with 3% discount rate. Probabilistic 
sensitivity analysis was also conducted. Results: Combination of trastuzumab 
and standard therapy compared with standard therapy in treatment of metastatic 
HER2-positive breast cancer resulted in addition of 170.9 million VND (658,8 vs 487,9 
million VND) and 0.81 QALY (1.77 vs 0.96). The incremental cost-effectiveness ratio 
resulted in VND 208,736,442.49/QALY, which was less than willing to Pay (WTP) of 
VietNam in 2013 (VND 253,503,360.00). Therefore, using trastuzumab in treatment 
of metastatic HER2-positive breast cancer women has been considered to be cost-
effective. Sensitivity analyisis showed that the most affecting factors on the cost-
utility of trastuzumab are trastuzumab’s price and patient’s weight. ConClusions: 
Trastuzumab in combination of standard therapy is cost-effective in treatment of 
metastatic HER2-positive breast cancer women in Vietnam. Trastuzumab’s price 
and patient’s weight are the most affecting factors on the cost-effectiveness of 
trastuzumab.
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wHat’s tHE oPtimal visual iNsPECtioN sCrEENiNg iNtErvals for 
CErviCal CaNCEr sCrEENiNg iN rEal PraCtiCE of rural CHiNa? a Cost-
utility moDEliNg stuDy
Li X.1, Goggins W.1, Zhao F.H.2, Qiao Y.L.3
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objeCtives: Chinese government initiated a nation-wide cervical screening pro-
gram, covering 10 million rural women in 221 counties all over the country. The 
objectives of the present study were to compare costs, health outcomes, and cost-
effectiveness of visual inspection with acetic acid (VIA) screening strategies in rural 
China, and to identify optimal screening intervals for policy makers. Methods: 
Markov simulation model was developed to synthesize the evidence of screening 
and treatment practices in rural China, and applied to predict the long-term costs 
and effectiveness for hypothetical cohorts over 20 years of screening. Model was 
validated by calibrating prediction with observation data on age-specific cervical 
cancer mortality and incidence in China. Costs were considered from a societal 
perspective while health effects were mainly expressed as quality-adjusted life 
years (QALY). Both cost and utility were collected on-site and discounted at 5% 
per year. Results: All completing alternatives showed certain benefits due to 
the decreased number of women developing cervical cancer. A trend for shorter 
screening intervals to have greater benefit was found. Under different screening 
intervals, mortality and incidence were expected to be reduced by 6.67-31.74% and 
5.12-23.60%, respectively. Comparing to no screening (status quo), ten-year VIA 
screening was identified as the most cost-effective option, followed by VIA screen-
ing every five-, three- and one year, with corresponding incremental cost-utility 
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between March and April 2014 and retrieved from an extra boost of ONCOVIEW 
database. ONCOVIEW is a continuous syndicated study on cancer treatment in 
the hospital setting, based on the collection of patient questionnaires. Patients 
inclusion criteria were the presence of an mCRC diagnosis, 3rd or later actual 
therapy line and no participation in a phase II or III clinical study. Information col-
lected included patient demographic characteristics, mCRC characteristics (TNM 
Classification, Karnofsky performance status scale and mutation analyses) and 
treatments (actual and previous schedules, dosages and durations). Furthermore, 
an evaluation of the “Rechallenge” occurrence, in other words the use in 3rd or 
later line of treatment of drugs previously used, has been performed. Results: 
261 patients diaries have been collected: 218 out of 261 patients were in third 
line of treatment, while 43 patients were in 4th or later treatment line. The 
most administered schema among third line patients was Capecitabine alone 
(63 patients), while the most used schema in fourth line was a combination of 
Fluorouracil and Folinic Acid (7 patients). About 40% of molecules administered 
in 3rd line and 67% of molecules administered in 4th line were used in previ-
ous lines. ConClusions: Results from the present study underline the unmet 
medical need in 3rd or later line of treatment of mCRC patients and the need for 
additional evidence-based treatment options.
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BurDEN of Drug wastE iN oNCology: oPtimizatioN of rEsourCE usE
Castro A.P., Alves A.F., Piedade A., Clark L.G.O, Bueno C.C., Minowa E.
Evidências Credibilidade Científica, São Paulo, Brazil
objeCtives: Minimizing waste of the use of drugs allows optimization of available 
resources in a scarce environment. Grouping patients may be an alternative to 
reduce drug waste in oncology. The aim of this study is to evaluate the economic 
impact of streamlined form of dispensation and percentage of drug wastage of 
the total drug expenditure in supplementary health system. Methods: Patients 
receiving antineoplasic treatment for stomach, colon, rectosigmoid, rectum, lung 
and breast cancer were eligible and selected retrospectively from the private mar-
ket administrative claims database (Evidencias database). Name and any other 
personal identification were not available at the database. Prescription and date 
of administration were collected from 3 selected private institutions consider-
ing large to small size in terms of patients. Waste of drug was calculated and it 
was defined as unavoidable or inappropriate clearance of partially drug use. All 
analyses were performed according to regimen and disease. Saving costs were 
calculated assuming minimization of waste by optimizing fully drug among group 
patients. Costs were derived from Simpro table. Exchange rate used was 1.00USD 
= 2.20BRL. Results: Seventeen drugs were identified among reported chemo-
therapy regimens in which 11 were analyzed due to potential of saving costs. From 
these, only 6 drugs could be rationalized. The optimization of drug dispensing 
would lead to a year savings of US$ 83.587,88, US$ 17.592,22 and US$ 8.225,24 to 
a large, medium and small clinic, respectively. Calculated drug wastage repre-
sented from 2% to 8% of the total drug expenditure, regarding on the antineoplastic 
used. Five of the 11 drugs did not cause savings due to small number of patients 
receiving those treatments. ConClusions: Grouping patients for drug wastage 
minimization is an effective way to reduce costs. Furthermore, savings can be 
increased by gathering patients of different diseases.
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rEsourCEs utilizatioN for tHE iNvEstigatioN of PulmoNary NoDulEs 
iN a uNivErsity HosPital CENtEr iN QuEBEC, CaNaDa
Gouault-Laliberté A.1, Bergeron C.2, Lachaine J.1
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objeCtives: Lung cancer is the leading cause of death among cancer patients; 
therefore, the detection of a pulmonary nodule cannot be ignored. With the 
increasing prevalence of lung nodule detection, the investigation requires a large 
number of health care resources. The objective of this study was to measure the 
health care resources used for the investigation of pulmonary nodules. Methods: 
A retrospective medical chart review was conducted at the CHUM-Hotel-Dieu in 
Montreal, Canada. Eligible patients were selected consecutively using the elec-
tronic appointment book of the pulmonary clinic, from January 1st 2011 to May 
23rd 2012. Inclusion criteria were: 40 year-old and over, presenting a pulmonary 
nodule ranging from 0.8 to 3.0 cm with no prior history of cancer in the last 
5 years and no history of lung cancer. Patient’s demographics, nodule charac-
teristics, medical information and resources utilization were extracted for 
each eligible patient. Results: A total of 47 patients (23 women and 24 men, 
mean age = 64) were included in the analysis. The mean nodule size was 1.8 
cm. Thirteen patients (28%) had a benign nodule and 34 (72%) had a malignant 
nodule. The most frequent non-invasive procedures were Thorax CT-Scan, PET-
Scan and Chest X-ray performed at least once in respectively 96%, 85% and 77% 
of patients. The minimally invasive procedures (bronchoscopy and transthoracic 
needle biopsy) and the invasive procedures (thoracoscopy and thoracotomy) 
were mostly performed in patients who were eventually diagnosed with a lung 
cancer. On average, patients with a benign nodule underwent 0.77 minimally 
invasive or invasive procedures vs. 1.94 for patients with a malignant nodule 
(p= 0.028). ConClusions: A significant amount of health care resources are 
deployed for the investigation of pulmonary nodules. This study tends to demon-
strate that minimally invasive and invasive procedures are mostly deployed for 
the diagnosis of malignant nodules.
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imPaCt oN HosPitalizatioN DErivED from tHE usE of DENosumaB for 
tHE PrEvENtioN of skElEtal-rElatED EvENts iN PatiENts witH BoNE 
mEtastasEs sECoNDary to BrEast CaNCEr iN gErmaNy
Diel I.1, Ikenberg R.2, Cristino J.3, Gatta F.3, Qian Y.4, Arellano J.4
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outcomes following BRCA testing in women with ovarian cancer and their female 
first-degree relatives. Two strategies are being compared: no testing versus BRCA 
testing. Estimates of cancer incidence and mortality, uptake and impact of risk-
reducing surgery and costs of BRCA testing, cancer treatment and palliative care 
were based on literature review. Outcomes are expressed as quality-adjusted life 
years (QALYs). One-way sensitivity analyses are conducted for key model param-
eters. Results: We first evaluated the cost-effectiveness of gene testing in relatives 
of ovarian cancer patients with BRCA mutations. Results showed this was associ-
ated with an ICER below the UK cost-effectiveness threshold of £20,000 per QALY 
gained compared with no testing. Sensitivity analyses showed the results were 
robust. ConClusions: We demonstrate that gene testing in unaffected female 
first-degree relatives of women with ovarian cancer due to BRCA mutations is cost 
effective. The final results will consider the cost effectiveness of offering BRCA 
testing to all eligible ovarian cancer cases and their unaffected female first-degree 
relatives.
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BurDEN of rENal imPairmENt: rElativE HEaltH CarE rEsourCE usE iN 
ProstatE CaNCEr PatiENts witH BoNE mEtastasEs
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objeCtives: Existing evidence suggests that around 49% of patients with bone 
metastases from solid tumors show evidence of renal impairment (eGFR< 60ml/
min/1.73m2) following diagnosis of bone metastases with approximately 80% of 
them developing chronic kidney disease. The objective of this analysis is to assess 
the economic and clinical burden of renal impairment in prostate cancer patients 
with bone metastases. Methods: Patients with a diagnosis of prostate cancer and 
bone metastases from the Adelphi Real World Disease Specific Programme USA 
2012 were included in the analyses. Propensity Score Matching was used; patients 
with evidence of renal impairment were matched with those without on a 1:1 basis, 
controlling for: age, BMI, smoking status, employment status, and relevant comor-
bidities. Outcomes included number of hospitalizations and length of stay in the 
past 12 months prior to the point of data collection. A Wilcoxon sign-rank test 
was used to quantify the impact of renal impairment. Results: 109 patients per 
group were included in the analyses (total 218). The renal impairment group was 
estimated to have an increased risk of inpatient visits of 63% (p= 0.036) compared 
to the control group (0.78 vs 0.48 inpatient visits per patient per year). Additionally, 
the renal impairment group had a mean of 2.43 (p= 0.027) more inpatient days per 
year than the control group (5.00 vs 2.56 inpatient days per patient per year). It was 
also observed that the patients in the renal impairment group were less likely to 
have received chemotherapy (37% vs 47% received chemotherapy). ConClusions: 
Findings suggest an increase in health care utilization in the hospital setting in 
prostate cancer patients with bone metastases and renal impairment. In addition, 
compromised renal function in those patients may potentially have restricted the 
use of nephrotoxic chemotherapy agents.
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EstimatiNg tHE voi of Pivotal stuDiEs towarDs PrEDiCtivE 
BiomarkErs of HigH DosE alkylatiNg CHEmotHEraPy iN triPlE 
NEgativE BrEast CaNCEr
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objeCtives: To estimate the expected benefits from a pivotal randomised con-
trolled trial of predictive biomarkers for high dose alkylating chemotherapy (HDAC) 
in triple negative breast cancer (TNBC) and to inform decisions about the design 
and priority of further studies. Methods: A markov decision model compared 
treating 40- years old TNBC women with HDAC based on four predictive biomarker 
strategies: 1) BRCA1-like by MLPA testing; 2) BRCA1-like by aCGH testing, 3) strategy 
1 followed by XIST and 53BP1 testing; and 4) strategy 2 followed by XIST and 53BP1 
testing, versus treating all patients with standard chemotherapy. A Dutch societal 
perspective and a 20-year time horizon were used. Input data came from literature 
and expert opinions. We assessed four primary outcomes: the expected value of 
(partial) perfect information (EV(P) PI), the expected value of sample information 
(EVSI) and the expected net benefit of sampling (ENBS) for the ongoing pivotal 
TNM trial (NCT01057069) and/or potential future studies. Results: The population 
EVPI was € 663 million (M). The EVPPI suggests prioritizing further research towards 
effectiveness parameters, specifically prevalence and positive predictive value of 
the biomarkers; response rates in biomarker negative patients and TNBC unclas-
sified patients, which are estimated to collectively have a value of information of 
circa € 630M. The value of further research on transition probabilities is estimated 
at € 41M, followed by utilities at € 34M and costs at € 34M. Further information on 
transition probabilities could be gathered from the TNM trial and that of effec-
tiveness parameters and costs from accompanying studies to this trial, altogether 
estimated to have an ENBS of € 657 M. ConClusions: Further research on predic-
tive biomarkers for HDAC should focus on gathering transition probability data 
from the current TNM trial, and on accompanying studies to derive data on other 
effectiveness parameters and costs.
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rEal worlD Data iN oNCology: tHirD- aND fourtH-liNE trEatmENts 
aDmiNistErED iN mEtastatiC ColoN-rECtal CaNCEr (mCrC)
Heiman F., Ripellino C., Visentin E.
CSD Medical Research S.r.l., Milan, Italy
objeCtives: The objective of this study was to assess the oncologists’ real clini-
cal practice in the management of mCRC patients, with a focus on the 3rd, 4th 
and later lines of therapy in Italy. Methods: Data presented in this study were 
collected from medical records obtained by Italian oncologists on mCRC patients 
